A Phase I Study of SGN-CD19B for Patients with Recurrent or Persistent B-Cell Non-Hodgkin Lymphoma

Full Title

A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19B in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma


The purpose of this study is to find the highest dose of an investigational drug called SGN-CD19B that can be given safely in patients with B-cell non-Hodgkin lymphoma (NHL) that has come back or continued to grow despite prior therapy. SGN-CD19B is an “antibody-drug conjugate” and has two parts: one (an antibody) that attaches to a protein called CD19 on the surface of NHL cells, and another (an anticancer drug) that kills the cancer. SGN-CD19B is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have diffuse large B-cell lymphoma or follicular lymphoma that came back or continued to grow after at least two prior regimens of chemotherapy.
  • At least 4 weeks must pass between the completion of previous therapies and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Craig Moskowitz at 212-639-2696.